Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 115

1.

Cyr61 is a potential prognostic marker for prostate cancer.

Terada N, Kulkarni P, Getzenberg RH.

Asian J Androl. 2012 May;14(3):405-8. doi: 10.1038/aja.2011.149. Epub 2012 Feb 20. Review.

2.

Decreased expression of Cyr61 is associated with prostate cancer recurrence after surgical treatment.

D'Antonio KB, Schultz L, Albadine R, Mondul AM, Platz EA, Netto GJ, Getzenberg RH.

Clin Cancer Res. 2010 Dec 1;16(23):5908-13. doi: 10.1158/1078-0432.CCR-10-1200.

3.

Cyr61 is regulated by cAMP-dependent protein kinase with serum levels correlating with prostate cancer aggressiveness.

Terada N, Shiraishi T, Zeng Y, Mooney SM, Yeater DB, Mangold LA, Partin AW, Kulkarni P, Getzenberg RH.

Prostate. 2012 Jun 15;72(9):966-76. doi: 10.1002/pros.21501. Epub 2011 Oct 24.

4.

Expression of Cyr61 in primary salivary adenoid cystic carcinoma and its relation to Ki-67 and prognosis.

Tang QL, Fan S, Li HG, Chen WL, Shen XM, Yuan XP, Chang SH, Song Y.

Oral Oncol. 2011 May;47(5):365-70. doi: 10.1016/j.oraloncology.2011.02.022. Epub 2011 Mar 24.

PMID:
21439895
5.

The potential value of microseminoprotein-beta as a prostate cancer biomarker and therapeutic target.

Whitaker HC, Warren AY, Eeles R, Kote-Jarai Z, Neal DE.

Prostate. 2010 Feb 15;70(3):333-40. doi: 10.1002/pros.21059. Review.

PMID:
19790236
6.

Extracellular matrix associated protein CYR61 is linked to prostate cancer development.

D'Antonio KB, Toubaji A, Albadine R, Mondul AM, Platz EA, Netto GJ, Getzenberg RH.

J Urol. 2010 Apr;183(4):1604-10. doi: 10.1016/j.juro.2009.12.006. Epub 2010 Feb 20.

7.

Cyr61: a potential therapeutic target for prostate cancer.

Lin CM, Liang CZ.

Asian J Androl. 2014 Sep-Oct;16(5):788-9. doi: 10.4103/1008-682X.128517. No abstract available.

8.

Cysteine-rich, angiogenic inducer, 61 expression in patients with ovarian epithelial carcinoma.

Lin Y, Xu T, Tian G, Cui M.

J Int Med Res. 2014 Apr;42(2):300-6. doi: 10.1177/0300060513505268. Epub 2014 Mar 4.

PMID:
24595148
9.

Expression of the extracellular matrix signaling molecule Cyr61 is downregulated in prostate cancer.

Pilarsky CP, Schmidt U, Eissrich C, Stade J, Froschermaier SE, Haase M, Faller G, Kirchner TW, Wirth MP.

Prostate. 1998 Jul 1;36(2):85-91.

PMID:
9655260
10.

Tissue metabolite profiling identifies differentiating and prognostic biomarkers for prostate carcinoma.

Jung K, Reszka R, Kamlage B, Bethan B, Stephan C, Lein M, Kristiansen G.

Int J Cancer. 2013 Dec 15;133(12):2914-24. doi: 10.1002/ijc.28303. Epub 2013 Jun 29.

11.

Involvement of Cyr61 in growth, migration, and metastasis of prostate cancer cells.

Sun ZJ, Wang Y, Cai Z, Chen PP, Tong XJ, Xie D.

Br J Cancer. 2008 Nov 18;99(10):1656-67. doi: 10.1038/sj.bjc.6604712. Epub 2008 Oct 21.

12.

Evaluation and prognostic significance of ACAT1 as a marker of prostate cancer progression.

Saraon P, Trudel D, Kron K, Dmitromanolakis A, Trachtenberg J, Bapat B, van der Kwast T, Jarvi KA, Diamandis EP.

Prostate. 2014 Apr;74(4):372-80. doi: 10.1002/pros.22758. Epub 2013 Dec 6.

PMID:
24311408
13.

Cyr61 is up-regulated in prostate cancer and associated with the p53 gene status.

Lv H, Fan E, Sun S, Ma X, Zhang X, Han DM, Cong YS.

J Cell Biochem. 2009 Mar 1;106(4):738-44. doi: 10.1002/jcb.22075.

PMID:
19180570
14.

STEAP1 protein overexpression is an independent marker for biochemical recurrence in prostate carcinoma.

Ihlaseh-Catalano SM, Drigo SA, de Jesus CM, Domingues MA, Trindade Filho JC, de Camargo JL, Rogatto SR.

Histopathology. 2013 Nov;63(5):678-85. doi: 10.1111/his.12226. Epub 2013 Sep 11.

PMID:
24025158
15.

Transcript levels of androgen receptor variant AR-V1 or AR-V7 do not predict recurrence in patients with prostate cancer at indeterminate risk for progression.

Zhao H, Coram MA, Nolley R, Reese SW, Young SR, Peehl DM.

J Urol. 2012 Dec;188(6):2158-64. doi: 10.1016/j.juro.2012.08.014. Epub 2012 Oct 22.

PMID:
23088973
16.

Comparison of the prognostic potential of hyaluronic acid, hyaluronidase (HYAL-1), CD44v6 and microvessel density for prostate cancer.

Ekici S, Cerwinka WH, Duncan R, Gomez P, Civantos F, Soloway MS, Lokeshwar VB.

Int J Cancer. 2004 Oct 20;112(1):121-9.

17.

Production of Cyr61 protein is modulated by extracellular acidification and PI3K/Akt signaling in prostate carcinoma PC-3 cells.

Lee YJ, Lee DM, Lee SH.

Food Chem Toxicol. 2013 Aug;58:169-76. doi: 10.1016/j.fct.2013.04.035. Epub 2013 Apr 24.

PMID:
23623839
18.

Cyr61 expression is associated with prognosis in patients with colorectal cancer.

Jeong D, Heo S, Sung Ahn T, Lee S, Park S, Kim H, Park D, Byung Bae S, Lee SS, Soo Lee M, Kim CJ, Jun Baek M.

BMC Cancer. 2014 Mar 7;14:164. doi: 10.1186/1471-2407-14-164.

19.

miRNAs as biomarkers in prostate cancer.

Casanova-Salas I, Rubio-Briones J, Fernández-Serra A, López-Guerrero JA.

Clin Transl Oncol. 2012 Nov;14(11):803-11. doi: 10.1007/s12094-012-0877-0. Epub 2012 Jul 24. Review.

PMID:
22855165
20.

A functional polymorphism in the CYR61 (IGFBP10) gene is associated with prostate cancer risk.

Tao L, Chen J, Zhou H, Qin C, Li P, Cao Q, Li J, Ju X, Zhu C, Wang M, Zhang Z, Shao P, Yin C.

Prostate Cancer Prostatic Dis. 2013 Mar;16(1):95-100. doi: 10.1038/pcan.2012.41. Epub 2012 Oct 9.

PMID:
23045290

Supplemental Content

Support Center